Form 4 CeriBell Inc: Josef Parvizi (Director) For: 16 November By Investing.com
This article reports on a Form 4 filing for CeriBell Inc, specifically detailing an insider transaction by Josef Parvizi, a director of the company. The filing pertains to activity on November 16. The piece provides the raw information without additional analysis or context.
Ceribell director Josef Parvizi sells $650,500 in shares
Josef Parvizi, a Director at Ceribell, Inc. (NASDAQ:CBLL), sold 25,000 shares of the company's common stock for a total of $650,500. These transactions were executed under a Rule 10b5-1 trading plan. The sale follows a significant surge in Ceribell stock over the past year and six months, and the company recently reported increased Q3 revenue despite a wider-than-expected loss.
Ceribell director Josef Parvizi sells $650,500 in shares By Investing.com
Ceribell director Josef Parvizi sold 25,000 shares of the company's common stock for a total of $650,500 on November 16, 2026, under a Rule 10b5-1 trading plan. This sale occurred after Ceribell's stock surged significantly over the past year, and despite analysts maintaining price targets above the sale price, InvestingPro analysis suggests the stock is currently overvalued. The company recently reported a 30% increase in Q3 revenue, although it posted a wider-than-expected loss per share.
A trust sells Ceribell (CBLL) shares at an average $26.02 under a preset trading plan.
The Innovation ACP Trust, associated with Ceribell, Inc. (CBLL) director Josef Parvizi, sold 25,000 common shares on November 16, 2026, at a weighted average price of $26.02 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted in August 2026. Following the transaction, the trust holds 882,911 shares, with Parvizi also reporting additional direct and indirect holdings through other trusts.
Ceribell (CBLL) director Burke sells 16,845 and 1,155 shares under a 10b5-1 plan.
Ceribell, Inc. (CBLL) director William W. Burke exercised options for 18,000 common shares on November 12, 2026, at an exercise price of $4.70 per share. He subsequently sold 16,845 shares at a weighted average price of $26.58 and an additional 1,155 shares at a weighted average price of $27.48. These transactions were conducted under a Rule 10b5-1 trading plan.
Form 144 Ceribell For: 12 November By Investing.com
The article reports on a Form 144 filing for Ceribell (CBLL) on November 12, 2026. This brief piece indicates a decline in Ceribell's stock by 5.22%. The content primarily highlights the financial reporting without providing further details on the nature of the filing or the reasons for the stock's performance.
Form 144 Ceribell For: 11 November By Investing.com
This article from Investing.com announces the filing of Form 144 for Ceribell on November 11. Form 144 is a notice of the intent to sell restricted securities. The brief article provides no further details beyond the announcement itself.
Is CeriBell (CBLL) Undervalued Following Its Higher 2026 Guidance And Delirium Launch?
CeriBell (CBLL) has increased its full-year 2026 revenue guidance to US$115-US$117 million and launched its FDA-cleared delirium monitoring solution with Medicare reimbursement. Despite significant share price gains over the past year, analysts at Simply Wall St believe the stock is still 7% undervalued, projecting a fair value of $29.57 per share against its current $27.48. The company's P/S ratio of 9.8x is considerably higher than the industry average, suggesting high market expectations for its growth.
Form 4 CeriBell Inc: Joseph Michael Taylor (Director) For: 9 November
This article reports on a Form 4 filing for CeriBell Inc., detailing an insider transaction by Joseph Michael Taylor, a Director, for November 9th. The filing indicates a change in ownership that investors might find relevant for understanding insider sentiment and company performance.
Ceribell director Joseph Taylor sells $277,644 of company stock By Investing.com
Joseph Michael Taylor, a director at Ceribell, Inc. (CBLL), recently sold 10,200 shares of company stock for a total of $277,644. This transaction occurred on November 9, 2026, with shares sold at a weighted average price of $27.22, as the stock traded near its 52-week high. Despite the company's impressive gross profit margins, analysts do not anticipate profitability this year, and InvestingPro analysis suggests the stock is overvalued.
Learn Why The Bull Case For CeriBell Stock Could Change Following Raised Revenue Guidance
CeriBell (NasdaqGS:CBLL) has raised its 2026 revenue outlook to US$115 million to US$117 million, driven by higher quarterly and year-to-date revenue and the commercial launch of its AI-powered delirium monitoring solution. While the company still operates at a significant net loss, the new Medicare add-on payment for delirium monitoring, not yet included in guidance, offers a fresh use case. The investment narrative now focuses on whether this increased guidance and new launch will lead to improved operating leverage and eventual profitability.
At $26.96 a share, Ceribell (CBLL) CTO Raymond Woo sells 4,887 shares.
Ceribell, Inc. CTO Raymond Woo sold 4,887 common shares at $26.96 per share on November 2, 2026. This transaction was part of a Rule 10b5-1 trading plan adopted on June 5, 2026. Prior to the sale, Woo also exercised options for 4,864 common shares at $3.65 each and 23 common shares at $4.70 each, all of which were fully vested.
CeriBell Q3 Earnings Call Highlights
CeriBell reported a 30% increase in Q3 revenue, reaching $29.3 million, driven by a record number of new hospital accounts and higher utilization of its seizure-monitoring platform. The company also announced the commercial launch of its Delirium Monitoring Solution and plans to introduce its next-generation Omni hardware platform in 2027. Despite widening net losses and increased operating expenses due to investments in infrastructure, CeriBell maintains high gross margins and expects to reach cash-flow breakeven with its current cash reserves.
CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions and 30% ...
CeriBell Inc. reported strong Q3 2026 results with a 30% revenue growth, reaching $29.3 million, driven by a record 35 new hospital additions and increased headband utilization. The company's gross margin improved to 90%, and its delirium monitoring solution pilot showed promising clinical impact and increased utilization. Despite these positives, the net loss widened to $21.4 million due to increased operating expenses, reflecting continued investment in growth.
Form 8K CeriBell Inc For: 3 November By Investing.com
This article reports that CeriBell Inc. filed a Form 8K on November 3, 2026. The filing is a standard disclosure document for significant events that a company must report to the SEC. The brief report mentions CeriBell Inc. (CBLL) stock performance, showing a 4.86% increase.
CeriBell Q3 2026 Earnings Call Transcript
CeriBell (NASDAQ: CBLL) announced its Q3 2026 financial results, reporting revenue of $29.3 million, a 30% year-over-year increase, driven by expanded hospital adoption and increased usage. The company launched its Delirium monitoring solution and plans a new Omni hardware platform for 2027, aiming to integrate multiple monitoring capabilities. CeriBell raised its full-year 2026 revenue guidance to $115 to $117 million, confident in its continued growth trajectory and strategic initiatives.
Ceribell Reports 30% Revenue Growth and 90% Gross Margin in Q3 2026
Ceribell (CBLL) reported strong third-quarter 2026 financial results, with revenue increasing 30% year over year to $29.3 million and a gross margin of 90%. Despite a net loss of $21.4 million, the company raised its full-year 2026 revenue outlook to $115 million to $117 million. Key business highlights include record new customer additions, double-digit same-store utilization growth, the launch of a delirium monitoring solution, and FDA clearance for Quantitative EEG Trending.
CeriBell, Inc. (CBLL) Misses Q3 EPS by 21c
CeriBell, Inc. (NASDAQ: CBLL) reported a Q3 EPS of ($0.55), which was $0.21 worse than the analyst estimate of ($0.34). The company's revenue for the quarter was $29.3 million, a significant increase from $0 reported in the same period last year. This earnings miss indicates that the company underperformed analyst expectations for the quarter.
Revenue rises 30% at Ceribell (CBLL) as losses widen and its 2026 outlook moves higher.
Ceribell (CBLL) reported a 30% increase in third-quarter 2026 revenue to $29.341 million, driven by strong growth in its core seizure business and increased utilization. Despite the revenue growth, the company's net loss widened to $21.351 million. Ceribell also raised its full-year 2026 revenue guidance to $115 million to $117 million, reflecting continued momentum.
Form 8K CeriBell Inc For: 3 November By Investing.com
This article reports on the filing of a Form 8K by CeriBell Inc. on November 3, 2026. The brief announcement from Investing.com indicates this is a financial market update. The Form 8K is a crucial SEC filing used to announce significant events that shareholders should know about.
Ceribell Reports Third Quarter 2026 Financial Results
Ceribell (Nasdaq: CBLL) reported strong financial results for the third quarter of 2026, with total revenue increasing 30% year-over-year to $29.3 million, driven by new account additions and increased utilization. The company achieved a gross margin of 90% and fully launched its delirium monitoring solution, positioning itself for continued growth in 2027. Despite an increase in operating expenses due to strategic investments, the company is raising its full-year 2026 revenue guidance to a range of $115 million to $117 million.
Delirium Monitor Launch Could Be A Game Changer For CeriBell Stock (CBLL)
CeriBell has commercially launched its FDA-cleared delirium monitoring solution, which combines continuous AI-based delirium and seizure monitoring, receiving a New Technology Add-on Payment from CMS of up to US$2,171 per eligible Medicare case. This development creates a stronger economic case for hospitals to adopt Ceribell's platform in ICUs, with the upcoming Q3 2026 earnings report expected to provide further insights into commercial rollout and utilization. Analysts anticipate significant revenue growth and a shift to profitability for CeriBell by 2028, projecting a US$75.4 million turnaround in earnings.
Delirium affects about 30% of ICU patients. Ceribell's bedside system monitors brain activity.
Ceribell (CBLL) has commercially launched its delirium monitoring solution, an expansion of its point-of-care brain monitoring platform. This FDA-cleared system uses AI-powered algorithms to continuously analyze brain activity for delirium screening and monitoring, leveraging the same hardware used for seizure detection. The Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare patient case for the solution, effective October 1, 2026, to help hospitals offset costs.
Ceribell Brings Continuous EEG-Based Delirium Monitoring to the Bedside
Ceribell has launched an AI-powered delirium monitoring solution on its point-of-care brain monitoring platform, combining seizure detection and delirium monitoring in one system. The platform, which received FDA clearance in December 2025, continuously analyzes EEG data for patterns associated with delirium and aids in screening and patient monitoring. The Centers for Medicare & Medicaid Services (CMS) has also approved a New Technology Add-on Payment (NTAP) for eligible Medicare patients using this solution.
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
Ceribell, Inc. has commercially launched its delirium monitoring solution, integrating it with its existing point-of-care brain monitoring platform for seizure detection. This FDA-cleared device uses AI-powered algorithms to continuously analyze brain activity, offering objective data to aid in delirium screening and monitoring, a condition often unrecognized through subjective assessments. The solution, which follows a successful pilot, has also been granted a New Technology Add-on Payment (NTAP) by CMS, making it more accessible to hospitals.
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
Ceribell has commercially launched its AI-enabled delirium monitoring solution on its point-of-care brain monitoring platform. This FDA-cleared device combines seizure detection and delirium monitoring in a single system, providing continuous, objective EEG-based insights to aid in delirium screening and monitoring. The launch follows a successful pilot and coincides with a New Technology Add-on Payment (NTAP) from CMS, which will help hospitals offset the cost of adopting this innovative technology.
Is CeriBell (CBLL) Fully Priced After A 133% One Year Run?
CeriBell (CBLL) has seen a 133.2% return over the past year, prompting questions about whether its current share price is justified by its sales performance. The company's stock currently trades at a P/S ratio of 10.0x, significantly higher than the Medical Equipment industry average of 2.7x and healthcare AI peers at 6.3x, suggesting it may be overvalued based on current revenue. Analysts and Simply Wall St Narratives provide further insights into future growth potential and profitability needed to support the current valuation.
Earnings Preview: Ceribell to Report Financial Results Post-market on November 03
This article provides an earnings preview for Ceribell, detailing that the company is scheduled to report its financial results post-market on November 3rd. Investors will be watching for key financial metrics and any updates on the company's performance and outlook.
CeriBell Inc stock hits 52-week high at 28.18 USD
CeriBell Inc. (CBLL) stock recently hit a 52-week high of $28.18, reflecting strong investor confidence despite being deemed overvalued by InvestingPro analysis. The company has shown impressive revenue growth and gross profit margins, with several analysts raising price targets due to new growth drivers and FDA approval for pediatric use.
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Ceribell, Inc. announced that its CFO, Scott Blumberg, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The event is scheduled for Wednesday, November 11, 2026, at 7:00 a.m. PST / 10:00 a.m. EST in New York City. A live and archived webcast will be available on the company's investor relations website.
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Ceribell, Inc. announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026. The medical technology company specializes in point-of-care EEG platforms for serious neurological conditions. A live and archived webcast of the event will be available on the company's investor relations website.
CeriBell, Inc. Estimates – NASDAQ:CBLL
This page provides financial estimates for CeriBell, Inc. (NASDAQ:CBLL) on TradingView. Users can explore reported financial data and analyst estimates for income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends over time. The platform offers both annual and quarterly data.
CeriBell, Inc. (CBLL) Stock Price, News, Quote & History
This article provides a detailed financial overview of CeriBell, Inc. (CBLL), a medical technology company. It covers stock price performance, key financial metrics, earnings trends, and analyst ratings, highlighting the company's focus on developing a point-of-care EEG platform. The data presented includes historical performance, market capitalization, revenue, and profitability.
Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
Ceribell, Inc. announced it will release its third-quarter 2026 financial results after market close on Tuesday, November 3, 2026. Following the release, company management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can access the call via phone or an archived webcast on the company's investor relations website.
Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
Ceribell, Inc. (Nasdaq: CBLL) announced it will release its third-quarter 2026 financial results after market close on Tuesday, November 3, 2026. The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Interested investors can access the call via a dial-in number or through the "Investor Relations" section of Ceribell's website.
Hospital Adoption Could Strengthen The Case For CeriBell Stock
CeriBell, a medical technology company, is seeing increased hospital adoption of its AI-enabled bedside EEG platform for real-time seizure detection. This growing utilization could boost recurring software and service revenue, influencing investor perception of its AI healthcare model. The article suggests that while CeriBell currently reports significant losses, the scaling of recurring revenue is a key factor for future profitability, with analysts forecasting substantial revenue growth and eventual earnings by 2028.
Hospital Adoption Could Strengthen The Case For CeriBell Stock
CeriBell's AI-enabled bedside EEG platform is gaining traction in hospitals as seizure management protocols become more common, leading to increased recurring software and service revenue. While the company currently reports significant losses, analysts forecast strong revenue growth and eventual profitability by 2028. This growing hospital adoption could be a key catalyst for CeriBell's investment narrative, with a fair value estimate suggesting potential upside.
CeriBell Inc stock hits 52-week high at 26.66 USD
CeriBell Inc. stock has reached a new 52-week high of $26.66 USD, reflecting a 109.17% increase over the past year. The medical device company now boasts a $1 billion market cap, an 88.9% gross profit margin, and 31.7% revenue growth. Despite strong performance, InvestingPro analysis suggests the stock might be overvalued, although analysts like TD Cowen, BTIG, and Raymond James have raised price targets, citing progress and growth drivers.
CeriBell (CBLL) Wins FDA Clearance, Is The Stock Now Too Expensive?
CeriBell (CBLL) recently received FDA clearance for new software for its Ceribell System, leading to significant stock price gains. Despite strong recent performance and projected revenue growth, the company's valuation, with a P/S ratio of 9.8x, is considered expensive compared to peers and the broader industry. The article suggests that while the FDA clearance is positive, the high valuation and continued losses present risks, prompting investors to assess if the upside is already priced in.
CeriBell (CBLL) Wins FDA Clearance, Is The Stock Now Too Expensive?
CeriBell (CBLL) recently received FDA clearance for new software for its Ceribell System, leading to significant stock price gains over the past year. Despite strong revenue growth forecasts, the company's Price-to-Sales ratio of 9.8x is considered expensive compared to peers and the broader industry, raising concerns about its valuation, especially given its unprofitability and reliance on a single product. Investors are advised to consider the embedded optimism and potential risks before making investment decisions.
Analysts’ Top NA Picks: Ceribell, Inc. (CBLL), CoreWeave (CRWV)
Two analysts have issued bullish sentiments on Ceribell, Inc. (CBLL) and CoreWeave (CRWV). Josh Jennings from TD Cowen maintained a Buy rating on Ceribell with a $33.00 price target, while Jefferies analyst Brent Thill reiterated a Buy rating on CoreWeave with a $150.00 price target. The analyst consensus suggests a Strong Buy for Ceribell with a 21.0% upside and a Moderate Buy for CoreWeave with a 62.6% upside.
Analysts’ Top NA Picks: Ceribell, Inc. (CBLL), CoreWeave (CRWV)
Analysts from TD Cowen and Jefferies have issued bullish sentiments on Ceribell, Inc. (CBLL) and CoreWeave (CRWV) respectively. Josh Jennings maintained a Buy rating on Ceribell with a $33.00 price target, while Brent Thill reiterated a Buy rating on CoreWeave with a $150.00 price target. The article highlights the current analyst consensus and potential upsides for both companies.
Ceribell CTO Raymond Woo sells $119,145 in company stock
Raymond Woo, CTO of Ceribell, Inc. (NASDAQ:CBLL), sold 4,887 shares of company stock for $119,145 after exercising stock options. Despite the company's impressive gross profit margins, analysts do not anticipate profitability this year. Several analyst firms have recently raised their price targets for Ceribell, citing growth drivers and leadership in point-of-care rapid EEG technology.
Form 4 CeriBell Inc For: 2 October
This article from Investing.com reports on a Form 4 filing for CeriBell Inc, dated October 2. Form 4 filings disclose changes in beneficial ownership of a company's securities by insiders, such as officers, directors, and significant shareholders. The brief piece indicates that CeriBell Inc's stock symbol is CBLL.
Ceribell CTO Raymond Woo sells $119,145 in company stock By Investing.com
Raymond Woo, CTO of Ceribell, Inc. (NASDAQ:CBLL), sold 4,887 shares of company stock for $119,145. This transaction followed the exercise of stock options and was executed under a Rule 10b5-1 trading plan. Despite the stock's 100% return over the past year, InvestingPro suggests it may be overvalued, although analysts from TD Cowen, BTIG, and Raymond James have recently raised price targets and maintained positive ratings for Ceribell.
Ceribell CTO Raymond Woo sells $119,145 in company stock By Investing.com
Ceribell CTO Raymond Woo sold 4,887 shares of company stock worth $119,145 on October 1, 2026, after exercising stock options. Despite the stock's 100% return over the past year, InvestingPro suggests it may be overvalued, and analysts do not anticipate profitability for Ceribell this year. Several analyst firms, including TD Cowen, BTIG, and Raymond James, have recently raised their price targets for Ceribell, citing positive outlooks and new growth drivers.
SSM Health touts seizure detection technology
SSM Health in Southern Illinois is now the first healthcare provider in the region to offer the Ceribell System, an FDA-cleared EEG technology for rapid detection of non-convulsive seizures. This system enhances neurological care for critically ill patients by providing faster diagnosis and treatment closer to home, available at SSM Health Good Samaritan Hospital in Mount Vernon and SSM Health St. Mary’s Hospital in Centralia. The technology helps clinicians quickly assess brain activity and continuously monitor patients, reducing the need for transfers and improving outcomes for challenging-to-detect non-convulsive seizures.
Option exercises accompany a 4,887-share sale at $24.38 by Ceribell (CBLL) CTO Raymond Woo.
Ceribell CTO Raymond Woo exercised options on October 1, 2026, to acquire a total of 4,887 shares (4,864 shares at $3.65 and 23 shares at $4.70) and subsequently sold all 4,887 shares at $24.38 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on June 5, 2026, and resulted in approximate gross sale proceeds of $119K and a pre-tax spread of $101K. After the transactions, Woo holds 67,658 stock option contracts and 203,118 common stock shares.
CeriBell Is Maintained at Buy by TD Cowen
This article states that TD Cowen has maintained its Buy rating for CeriBell. The content of the article itself is missing, so no further details can be provided.
TD Cowen maintains Buy rating on CeriBell, $33 price target
TD Cowen has reiterated its Buy rating on CeriBell's stock, setting a price target of $33.00, which suggests a 39.8% upside from its recent closing price. The positive outlook is attributed to the anticipated improvement in CeriBell's sales force productivity and the significant market opportunity for its Ceribell System in critical care settings.